Tianjin Chase Sun Pharmaceutical Co.,Ltd

Shenzhen Stock Exchange 300026.SZ

Tianjin Chase Sun Pharmaceutical Co.,Ltd Gross Profit Margin for the year ending December 31, 2023: 53.67%

Tianjin Chase Sun Pharmaceutical Co.,Ltd Gross Profit Margin is 53.67% for the year ending December 31, 2023, a -7.03% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.
  • Tianjin Chase Sun Pharmaceutical Co.,Ltd Gross Profit Margin for the year ending December 31, 2022 was 57.73%, a -0.36% change year over year.
  • Tianjin Chase Sun Pharmaceutical Co.,Ltd Gross Profit Margin for the year ending December 31, 2021 was 57.93%, a 2.46% change year over year.
  • Tianjin Chase Sun Pharmaceutical Co.,Ltd Gross Profit Margin for the year ending December 31, 2020 was 56.54%, a -16.63% change year over year.
  • Tianjin Chase Sun Pharmaceutical Co.,Ltd Gross Profit Margin for the year ending December 31, 2019 was 67.82%, a -4.49% change year over year.
Key data
Date Gross Profit Margin Operating Income Margin EBT Margin Net Income Margin
Market news
Shenzhen Stock Exchange: 300026.SZ

Tianjin Chase Sun Pharmaceutical Co.,Ltd

CEO Ms. Dan Zheng
IPO Date Oct. 30, 2009
Location China
Headquarters No. 20, Quanfa Road
Employees 5,910
Sector Health Care
Industries
Pharmaceuticals
Description

Tianjin Chase Sun Pharmaceutical Co.,Ltd engages in the research, development, production, and marketing of various pharmaceutical products in China. The company offers Chinese herb preparation products, medicinal granules, synthetic drugs, biotech drugs, medical apparatus, and Internet based therapy. It is also involved in the research and development of various drugs in the areas of sepsis, pulmonary hypertension, leukemia, cardiovascular and cerebrovascular diseases, arthritis, ischemic stroke, HCV, vascular disease, psychosis, and chemotherapy, as well as anesthesia drugs and immunomodulators. The company was founded in 1996 and is based in Tianjin, China.

StockViz Staff

January 15, 2025

Any question? Send us an email